NovaBay End Period Cash Flow from 2010 to 2025
| NBY Stock | USD 0.61 0.01 1.53% |
End Period Cash Flow | First Reported 2006-12-31 | Previous Quarter 751 K | Current Value 1.3 M | Quarterly Volatility 3.4 M |
Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0638, Dividend Yield of 0.0 or PTB Ratio of 0.28. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
NovaBay | End Period Cash Flow |
Latest NovaBay Pharmaceuticals' End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of NovaBay Pharmaceuticals over the last few years. It is NovaBay Pharmaceuticals' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
NovaBay End Period Cash Flow Regression Statistics
| Arithmetic Mean | 6,544,253 | |
| Geometric Mean | 5,659,237 | |
| Coefficient Of Variation | 53.05 | |
| Mean Deviation | 2,897,903 | |
| Median | 6,138,653 | |
| Standard Deviation | 3,471,626 | |
| Sample Variance | 12.1T | |
| Range | 10.5M | |
| R-Value | (0.18) | |
| Mean Square Error | 12.5T | |
| R-Squared | 0.03 | |
| Significance | 0.51 | |
| Slope | (130,147) | |
| Total Sum of Squares | 180.8T |
NovaBay End Period Cash Flow History
About NovaBay Pharmaceuticals Financial Statements
NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 3.2 M | 6.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.